NSCLC

Expert Sound Bites

OL5M20S

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

OL2M58S

EGFR-Targeted Therapy Sequencing After Resistance in NSCLC

OL2M58S

Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response

OL2M58S

Access to Molecular Testing Across Institutions: Barriers, Resources, and Real-World Solutions

OL2M58S

Adapting to Tumor Evolution: Resistance Mechanisms and Sequencing After Progression

OL3M37S

Biomarker Testing in NSCLC: Tissue and Liquid Biopsy for Precision Therapy

3:54

New Treatment Options in HER2 NSCLC: Expert Insights for Optimizing Therapy with Zongertinib

3:53

RAS in NSCLC: Progress in Targeting a Historically “Undruggable” Oncogene

2:45

MTAP in NSCLC: Updates in Biomarker and Drug Development

3:02

Optimizing Treatment with Dato-DXd in Advanced EGFRm NSCLC

1:50

Optimizing Treatment with Teliso-V in NSCLC

2:24

Biomarker Testing Best Practices: cMET Overexpression in NSCLC

3:44

Expert Insights for Prioritizing Therapeutic Targets in Advanced NSCLC

4:21

AE Management Strategies for ROS1-Targeted Therapies in NSCLC

3:45

Navigating Frontline Treatment Options in ROS1+ NSCLC

3:37

Testing for ROS1 Rearrangements in NSCLC

1:56

Adverse Event Management Strategies for HER2-Targeted Therapies in Advanced NSCLC

1:18

Navigating Treatment Options in Advanced NSCLC with HER2 Mutations

1:08

Testing for HER2 Mutations in Advanced NSCLC

1:40

Adverse Event Management Strategies for NTRK-Targeted Therapies in Advanced NSCLC

1:08

Navigating Frontline Treatment Options in Advanced NSCLC with NTRK Gene Fusions

1:08

Testing for NTRK Gene Fusions in Advanced NSCLC

2:11

Adverse Event Management Strategies for RET-Targeted Therapies in Advanced NSCLC

1:21

Navigating Frontline Treatment Options in Advanced NSCLC with RET Alterations

1:41

Testing for RET Rearrangements in Advanced NSCLC

1:12

Expert Insights on Managing Oligometastatic Disease Progression in Advanced EGFR-Mutant NSCLC

1:33

Treatment Strategies for Advanced EGFR-Mutant NSCLC with CNS Involvement

2:32

Adverse Event Management Strategies for Amivantamab-Based Combinations in Advanced NSCLC

2:04

Optimizing Patient Selection and Treatment Management with Amivantamab-Based Combination Therapy in Advanced NSCLC

1:41

Adverse Event Management and Therapy Optimization with EGFR TKIs in Advanced NSCLC

2:34

Optimizing Patient Selection and Treatment Management with the FLAURA2 Regimen in Advanced EGFRm NSCLC

2:28

Navigating Frontline Treatment Options in Advanced EGFRm NSCLC

2:30

Optimizing Patient Selection and Treatment Management with the LAURA Regimen in Early-Stage NSCLC

1:25

Biomarker Testing in NSCLC: Assessing for EGFR Mutations in Early and Advanced Stage Disease

2:27

Navigating Treatment Options for Patients with Advanced NSCLC and STK11 KEAP1, and KRAS Mutations

2:19

Adverse Event Monitoring and Management Strategies for ALK-Targeted Therapies in Advanced NSCLC

1:22

Navigating Frontline Treatment Options in Advanced ALK+ NSCLC

0:59

Leveraging Liquid Biopsy to Guide ALK Inhibitor Therapy in Advanced NSCLC

2:21

Testing for ALK Rearrangements in Advanced NSCLC

4:25

AE Monitoring and Management Strategies for MET Inhibitors in NSCLC

2:57

Navigating Frontline Treatment Options in NSCLC with METex14 Mutations

2:43

Rationale and Insights: Testing for MET Alterations in NSCLC

2:02

AE Monitoring and Management Strategies for BRAF V600E-Targeted Therapies in NSCLC

4:13

Navigating Frontline Treatment Options in BRAF V600E-Mutant NSCLC

0:58

Rationale and Insights: Testing for BRAF Mutations in NSCLC

1:45

Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC

2:06

Dr Kim on NSCLC Treatment Selection Based on Biomarker Testing Results

3:23

Dr Olazagasti on the Use of Biomarker Testing in Lung Cancer

5:07

Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

3:07

Dr Schneider on Diagnostic Testing Turnaround Times in Lung Cancer

3:09

What are the Benefits and Side Effects of Immunotherapy?

1:18

What are Challenges Around Access to Testing?

0:43

What is Chromosomal Rearrangement?

0:32

What is a Gene Mutation and a Gene Fusion?

1:20

What is a Biomarker in the Context of Tumors?

1:43

What are the Benefits and Side Effects of TKIs?

0:45

Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

0:50

What is DNA and RNA Testing in Biomarker Testing?

0:40

What is NGS Testing?

2:12

Addressing Concerns Regarding Biomarker Testing

2:24

How is Biomarker Testing Performed and Utilized?

4:14

Interpreting the Results of an NGS Testing Report

1:55

Key Elements of an NGS Testing Report

1:05

When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?

1:11

How Do You Explain Adjuvant Therapy in NSCLC?

1:55

How Do You Explain Neoadjuvant Therapy in NSCLC?

3:33

Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retroscpective Observational Study

4:08

Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study

1:14

Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS

2:35

Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort